Beyond IgG: Nanobodies and the Next Generation of Diagnostics & Therapeutics
How single-domain antibodies and next-generation discovery platforms are reshaping diagnostics, therapy, and drug development — from antibody discovery to "Antibody+" medicines.
The third episode of NAPPA Healthcare & Biopharma Insights moves from deal-making to the science underneath it. Conventional IgG antibodies have anchored the biologics industry for decades, but their size and architecture limit what they can reach. Nanobodies — single-domain antibodies roughly a tenth the mass of an IgG — open targets and formats that full-length molecules cannot.
Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen, works at the front of that shift, building discovery platforms that span single-domain, common light chain, and full-length antibodies, with applications running from diagnostics into mRNA therapeutics and gene and cell therapy. This hour traces the path from discovery platform to what he calls “Antibody+” medicines, and where the practical advantages — and the limits — actually lie.
The session is open to NAPPA members, partners, and qualified industry guests. Register below to receive Zoom join details.
Key topics.
- ✓ What nanobodies are, and how they differ from conventional IgG
- ✓ Single-domain, common light chain, and full-length antibody discovery
- ✓ Next-generation antibody discovery platforms
- ✓ From antibody discovery to Antibody+ medicines
- ✓ Applications across diagnostics, therapy, and drug development
- ✓ mRNA therapeutics and gene & cell therapies
Understand how single-domain antibodies differ from conventional IgG, and where that difference matters.
Compare single-domain, common light chain, and full-length discovery routes for a given program.
See where nanobodies are reshaping diagnostics, therapy, and drug development.
Learn from a founder building next-generation discovery platforms and global partnerships.
This event has already taken place.
Registration closed on Saturday, September 19, 2026. Thanks to everyone who joined us live. Check the Events page for upcoming episodes in the NAPPA Healthcare & Biopharma Insights series.